US Patent

US11628200 — Glycopeptide compositions

Formulation · Assigned to Xellia Pharmaceuticals ApS · Expires 2035-11-06 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for manufacturing and using stable glycopeptide antibiotic solutions, such as those containing Vancomycin, with added amino acids or derivatives.

USPTO Abstract

Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.

Drugs covered by this patent

Patent Metadata

Patent number
US11628200
Jurisdiction
US
Classification
Formulation
Expires
2035-11-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Xellia Pharmaceuticals ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.